296 related articles for article (PubMed ID: 34427044)
1. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
Yalcin Kehribar D; Gunaydin S; Ozgen M
Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
[TBL] [Abstract][Full Text] [Related]
2. Infliximab treatment in refractory vascular Behcet's disease: A single-center experience.
Kehribar DY; Ozgen M
Vascular; 2020 Dec; 28(6):829-833. PubMed ID: 32448079
[TBL] [Abstract][Full Text] [Related]
3. Neurological Sequelae in Youngest Adult Behcet's Disease Patient on Infliximab.
Sultan M; Khan A; Habib SS; Hayat M
J Coll Physicians Surg Pak; 2020 Jul; 30(7):762-764. PubMed ID: 32811612
[TBL] [Abstract][Full Text] [Related]
4. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia.
Houman MH; Bellakhal S; Ben Salem T; Hamzaoui A; Braham A; Lamloum M; Monia SK; Ben Ghorbel I
Clin Neurol Neurosurg; 2013 Oct; 115(10):2015-8. PubMed ID: 23830180
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
7. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq.
Al-Araji A; Sharquie K; Al-Rawi Z
J Neurol Neurosurg Psychiatry; 2003 May; 74(5):608-13. PubMed ID: 12700303
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging findings and outcome of neuro-Behçet's disease: the predictive factors.
Farahangiz S; Sarhadi S; Safari A; Borhani-Haghighi A
Int J Rheum Dis; 2012 Dec; 15(6):e142-9. PubMed ID: 23253242
[TBL] [Abstract][Full Text] [Related]
11. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.
Bolek EC; Sari A; Kilic L; Kalyoncu U; Kurne A; Oguz KK; Topcuoglu MA; Ertenli I; Karadag O
Mult Scler Relat Disord; 2020 Feb; 38():101512. PubMed ID: 31733425
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
14. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
15. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
16. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
Yoon DL; Kim YJ; Koo BS; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2014 May; 17(4):453-8. PubMed ID: 24506839
[TBL] [Abstract][Full Text] [Related]
17. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Barešić M; Reihl M; Habek M; Vukojević N; Anić B
Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
[TBL] [Abstract][Full Text] [Related]
18. Neurological complications of Behçet's syndrome.
Kidd D
Curr Neurol Neurosci Rep; 2012 Dec; 12(6):675-9. PubMed ID: 23007835
[TBL] [Abstract][Full Text] [Related]
19. Effect of Infliximab on Chronic Progressive Neuro-Behçet's Disease: Influence of the Timing of Introduction on the Patient Outcome.
Hirohata S; Kikuchi H; Sawada T; Kuwana M; Kawachi I; Kirino Y; Ishigatsubo Y; Takeno M
Intern Med; 2024 Feb; 63(4):481-486. PubMed ID: 37344428
[TBL] [Abstract][Full Text] [Related]
20. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
